Skip to main content
. Author manuscript; available in PMC: 2014 Sep 9.
Published in final edited form as: Cochrane Database Syst Rev. 2011 Dec 7;(12):CD006528. doi: 10.1002/14651858.CD006528.pub2

Comparison 5. Mirtazapine versus newer antidepressants.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Primary outcome (response) at 2 weeks 1 40 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.18, 5.67]
 1.1 vs Reboxetine 1 40 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.18, 5.67]
2 Primary outcome (response) at end of the acute-phase treatment 1 40 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.27, 3.67]
 2.1 vs Reboxetine 1 40 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.27, 3.67]
3 Secondary outcome (remission) at 2 weeks 1 40 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.06, 17.18]
 3.1 vs Reboxetine 1 40 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.06, 17.18]
4 Secondary outcome (remission) at end of the acute-phase treatment 1 40 Odds Ratio (M-H, Random, 95% CI) 1.26 [0.33, 4.73]
 4.1 vs Reboxetine 1 40 Odds Ratio (M-H, Random, 95% CI) 1.26 [0.33, 4.73]
5 Secondary outcome (depression severity) at 2 weeks 1 40 Std. Mean Difference (IV, Random, 95% CI) −0.37 [−1.00, 0.25]
 5.1 vs Reboxetine 1 40 Std. Mean Difference (IV, Random, 95% CI) −0.37 [−1.00, 0.25]
6 Secondary outcome (withdrawal due to any reason) 2 80 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 6.1 vs Reboxetine 2 80 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Secondary outcome (withdrawal due to adverse events) 2 80 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 7.1 vs Reboxetine 2 80 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Secondary outcome (SKEWED DATA: depression severity) at end of the acute-phase treatment Other data No numeric data